scorecardresearchDr. Lal Pathlabs Share Price 2,217.00
Mintgenie
Mintgenie

Dr. Lal Pathlabs

BSE: 539524 | NSE: LALPATHLAB | ISIN: INE600L01024 | SECTOR: Healthcare Facilities

₹2,217.00 18.00 (0.82%)

05 Jul 2022, 09:59 (IST)

  • Open

    2,212.10

  • High

    2,232.20

  • Low

    2,185.05

  • Prev Close

    2,199.00

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    -

  • Volume

    8.20K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    2,217.00

  • Ask

    -
View all metrics
  • 2,185.05
  • Intraday
  • 2,232.20
  • 1,805.10
  • 52 Wk H/L
  • 4,243.00
  • 1,979.10
  • DPR
  • 2,418.90

Key Metrics

- Mkt. Cap.

V

Volatility %

B

Beta -

Genie Says

Financials

  • Annual
  • Quarterly
  • Actuals
  • Forecasted

Revenue vs. Profit Trend

No Chart data available
View all

Peer Comparison

  • Price Comparison
  • Ratios Comparison
No data available
CompanyLatest Price
Change (% Chg)		52 Week
High		52 Week
Low		Market Cap.
(Cr)
View all

Events

  • Dividends
  • Bonus
  • Splits
  • Rights
  • Board Meetings
  • Annual General Meetings

Ex-Dividend

Div Value

Description

    View all

    Simple Moving Averages

    DaysBSENSE

    Dr. Lal Pathlabs is trading higher than 5 day, 20 day, 100 day and 200 day moving averages.

    News

    View all

    Company Description

    • Large Cap
    • Automobiles

    • BSE

      539524

    • NSE

      LALPATHLAB

    • ISIN

      INE600L01024

    Dr. Lal PathLabs Limited is engaged in providing diagnostic and related healthcare tests and services. The Company is also engaged in running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, and other pathological and radiological investigations. The Company offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder and viral infections. The Company’s subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, Dr. Lal PathLabs Nepal Private Limited, Dr. Lal PathLabs Bangladesh Pvt. Ltd. and Dr. Lal Ventures Private Limited.

    Company Officers

    • Arvind Lal

      Executive Chairman of the Board

    • Bharath Uppiliappan

      Chief Executive Officer

    • Ved Goel

      Chief Financial Officer

    • Rajat Kalra

      Compliance Officer, Company Secretary and Legal Head

    • Om Manchanda

      Managing Director, Executive Director

    • Vandana Lal

      Executive Director